Dental products company Dentsply Sirona (NASDAQ:XRAY) fell short of the market’s revenue expectations in Q3 2026, with revenue falling 7.5% year on year to $836 million. The company’s full-year revenue guidance of $3.5 billion at the midpoint came in 1.9% below analysts’ consensus estimates. Its non-GAAP profit of $0.29 per share was 6.2% below analysts’ consensus estimates.
Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.
Detailed price information for Dentsply Sirona Inc (XRAY-Q) from The Globe and Mail including charting and trades.
The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona’s North American dealer network and giving more customers access to its products and technology.CHARLOTTE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona (Nasdaq: XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced an expanded relationship with Midwest Dental Equipment & Supply, an independent, family-owned distri
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how dental equipment & technology stocks fared in Q2, starting with Dentsply Sirona (NASDAQ:XRAY).
DENTSPLY SIRONA (XRAY) shares are in focus after the company reported second quarter 2026 results that returned the business to profitability while net sales declined 4.1% year over year. The latest results and upcoming appearance at the Baird 2026 Global Healthcare Conference come after a mixed share price pattern for DENTSPLY SIRONA, with a 7 day share price return of 3.53% but a 30 day share price return that declined 19.90%. Recent momentum has been choppy, as a 90 day share price return...
DENTSPLY SIRONA stock has had a difficult run over the past few years, yet on broad valuation checks it now screens as one of the cheaper options in its peer group. The share price history and the current multiples are sending very different signals about what the market expects from the business. Over the past 5 years, DENTSPLY SIRONA shareholders have seen the stock fall about 79.6%, which points to a long period of weak sentiment that still weighs on expectations today. The valuation...
Dentsply Sirona recently reported second-quarter 2026 results showing a 4.1% year-over-year net sales decline but a return to net income, with higher margins and stronger cash generation, and also confirmed it will present at the Baird 2026 Global Healthcare Conference on September 15, 2026. The combination of improved profitability and cash flow, despite weaker revenue and a history of pressure on returns, led management to reiterate full-year 2026 guidance, highlighting a sharper focus on...
CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global Healthcare Conference. Management is scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://inves
On August 6, Dentsply Sirona (NASDAQ:XRAY) reported second-quarter 2026 results that pulled the stock in two directions at once. Net sales fell 4.1% year over year to $898 million, yet the company swung from a $45 million net loss a year earlier to $37 million in net income, with diluted earnings per share of $0.18 […]
This is the newest page. Registered accounts read further back.